{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:08:21Z","timestamp":1761332901559,"version":"build-2065373602"},"reference-count":28,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease\ncharacterized by progressive swelling and stiffness in the joints. Mavrilimumab is a human monoclonal\nantibody that may block the autoimmune mechanism of the antibodies causing RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We aim to assess the safety and efficacy of Mavrilimumab in treating rheumatoid arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted an online search using PubMed, Scopus, Web of Science, and Cochrane\nCENTRAL till June 2019, and updated the search in May 2020, using relevant keywords. We\nscreened studies for eligibility. Data were extracted from eligible studies and pooled as Risk ratio\n(RR) with a 95% confidence interval (CI), using Review Manager software (ver.3.5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Five studies (with 1145 patients) were eligible to our criteria. Pooled result from three\ntrials showed a significant reduction in Disease Activity Score 28 based on C-reactive protein\n(DAS28-CRP) remission &lt; 2.6 after 12 weeks (RR = 3.31, 95% CI [1.53, 7.18], P = 0.002), American\nCollege of Rheumatology (ACR) 20, after 12 weeks (RR = 2.38, 95% CI [1.80, 3.16], P &lt;\n0.00001), ACR 50, after 12 weeks (RR = 2.93, 95% CI [1.67, 5.15], P = 0.0002), ACR 70, after 12\nweeks (RR = 4.90, 95% CI [1.60, 15.00], P = 0.005). Mavrilimumab not associated with a significant\nadverse event (RR = 1.22, 95% CI [0.89, 1.68], P = 0.22).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We found that subcutaneous Mavrilimumab was effective and well-tolerating in treating\nRA patients, with no significant adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1573397116666201113085444","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T07:02:18Z","timestamp":1605250938000},"page":"184-192","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and Efficacy of Mavrilimumab For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis"],"prefix":"10.2174","volume":"17","author":[{"given":"Laila Salah","family":"Shamseldin","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Tanta University, Tanta,Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Mohamed","family":"Shawqi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Benha University, Benha,Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor Adel","family":"Al Hashem","sequence":"additional","affiliation":[{"name":"Faculty of Dentistry, University of Jordan, Amman,Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majd Aleslam Hussein","family":"Alhyari","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Jordan, Amman,Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossam Aldein Samir","family":"Abd Elazeem","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Assuit University, Assuit,Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrouk M.","family":"Elghazaly","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Assuit University, Assuit,Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5269-9421","authenticated-orcid":true,"given":"Aboalmagd","family":"Hamdallah","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University, Damietta,Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled Mohamed","family":"Ragab","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Minia University, Minya,Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas Zakarya","family":"Nourelden","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University, Cairo,Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-018-8714-z","volume":"58","author":"Carbone F.","year":"2020","unstructured":"Carbone F.; Bonaventura A.; Liberale L.; Paolino S.; Torre F.; Dallegri F.; Atherosclerosis in rheumatoid arthritis: Promoters and opponents. Clin Rev Allergy Immunol Springer 2020,58(1),1-14","journal-title":"Clin Rev Allergy Immunol Springer"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"Smolen J.S.","year":"2016","unstructured":"Smolen J.S.; Aletaha D.; McInnes I.B.; Rheumatoid arthritis. Lancet 2016,388(10055),2023-2038","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.5606\/ArchRheumatol.2018.6480","volume":"33","author":"Tuncer T.","year":"2017","unstructured":"Tuncer T.; Gilgil E.; Ka&#xE7;ar C.; Kurtai&#x15F; Y.; Kutlay &#x15E;.; B&#xFC;t&#xFC;n B.; Yal&#xE7;in P.; Akarirmak &#xDC;.; Altan L.; Ardi&#xE7; F.; Ardi&#xE7;o&#x11F;lu &#xD6;.; Altay Z.; Cant&#xFC;rk F.; Cerraho&#x11F;lu L.; &#xC7;evik R.; Demir H.; Durmaz B.; Dursun N.; Duru&#xF6;z T.; Erdo&#x11F;an C.; Evcik D.; G&#xFC;rsoy S.; Hizmetli S.; Kaptano&#x11F;lu E.; Kayhan &#xD6;.; Kirnap M.; Kokino S.; Kozano&#x11F;lu E.; Kuran B.; Nas K.; &#xD6;ncel S.; Sindel D.; Orkun S.; Sarpel T.; Sava&#x15F; S.; &#x15E;endur &#xD6;.F.; &#x15E;enel K.; U&#x11F;urlu H.; Uzunca K.; Tekeo&#x11F;lu \u0130.; Guillemin F.; Prevalence of rheumatoid arthritis and spondyloarthritis in Turkey: A nationwide study. Arch Rheumatol 2017,33(2),128-136","journal-title":"Arch Rheumatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/1753-0407.12856","volume":"11","author":"Bao Y.K.","year":"2019","unstructured":"Bao Y.K.; Weide L.G.; Ganesan V.C.; Jakhar I.; McGill J.B.; Sahil S.; Cheng A.L.; Gaddis M.; Drees B.M.; High prevalence of comorbid autoimmune diseases in adults with type 1 diabetes from the HealthFacts database. J Diabetes 2019,11(4),273-279","journal-title":"J Diabetes"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00296-017-3726-1","volume":"37","author":"Hunter T.M.","year":"2017","unstructured":"Hunter T.M.; Boytsov N.N.; Zhang X.; Schroeder K.; Michaud K.; Araujo A.B.; Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int 2017,37(9),1551-1557","journal-title":"Rheumatol Int"},{"key":"ref=6","author":"Lanzillo C.F.","year":"2014","unstructured":"Lanzillo C.F.; Hayden S.R.;  Rosen and Barkin\u2019s 5-Minute Emergency Medicine Consult: Fifth Edition Wolters Kluwer Health Adis (ESP) 2014","journal-title":"Rosen and Barkin\u2019s 5-Minute Emergency Medicine Consult: Fifth Edition Wolters Kluwer Health Adis (ESP)"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"Smolen J.S.","year":"2017","unstructured":"Smolen J.S.; Landew&#xE9; R.; Bijlsma J.; Burmester G.; Chatzidionysiou K.; Dougados M.; Nam J.; Ramiro S.; Voshaar M.; van Vollenhoven R.; Aletaha D.; Aringer M.; Boers M.; Buckley C.D.; Buttgereit F.; Bykerk V.; Cardiel M.; Combe B.; Cutolo M.; van Eijk-Hustings Y.; Emery P.; Finckh A.; Gabay C.; Gomez-Reino J.; Gossec L.; Gottenberg J.E.; Hazes J.M.W.; Huizinga T.; Jani M.; Karateev D.; Kouloumas M.; Kvien T.; Li Z.; Mariette X.; McInnes I.; Mysler E.; Nash P.; Pavelka K.; Po&#xF3;r G.; Richez C.; van Riel P.; Rubbert-Roth A.; Saag K.; da Silva J.; Stamm T.; Takeuchi T.; Westhovens R.; de Wit M.; van der Heijde D.; EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017,76(6),960-977","journal-title":"Ann Rheum Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone E.C.","year":"2004","unstructured":"Keystone E.C.; Kavanaugh A.F.; Sharp J.T.; Tannenbaum H.; Hua Y.; Teoh L.S.; Fischkoff S.A.; Chartash E.K.; Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004,50(5),1400-1411","journal-title":"Arthritis Rheum"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/BF00262295","volume":"14","author":"Bell A.L.","year":"1995","unstructured":"Bell A.L.; Magill M.K.; McKane W.R.; Kirk F.; Irvine A.E.; Measurement of colony-stimulating factors in synovial fluid: potential clinical value. Rheumatol Int 1995,14(5),177-182","journal-title":"Rheumatol Int"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nri2356","volume":"8","author":"Hamilton J.A.","year":"2008","unstructured":"Hamilton J.A.; Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008,8(7),533-544","journal-title":"Nat Rev Immunol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.it.2012.08.006","volume":"34","author":"Hamilton J.A.","year":"2013","unstructured":"Hamilton J.A.; Achuthan A.; Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol 2013,34(2),81-89","journal-title":"Trends Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc2843","volume":"10","author":"Metcalf D.","year":"2010","unstructured":"Metcalf D.; The colony-stimulating factors and cancer. Nat Rev Cancer 2010,10(6),425-434","journal-title":"Nat Rev Cancer"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.immuni.2015.08.010","volume":"43","author":"Croxford A.L.","year":"2015","unstructured":"Croxford A.L.; Lanzinger M.; Hartmann F.J.; Schreiner B.; Mair F.; Pelczar P.; Clausen B.E.; Jung S.; Greter M.; Becher B.; The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity. Immunity 2015,43(3),502-514","journal-title":"Immunity"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nrrheum.2009.178","volume":"5","author":"Cornish A.L.","year":"2009","unstructured":"Cornish A.L.; Campbell I.K.; McKenzie B.S.; Chatfield S.; Wicks I.P.G-C.S.F.; G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009,5(10),554-559","journal-title":"Nat Rev Rheumatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/1759720X17752036","volume":"10","author":"Cook A.D.","year":"2018","unstructured":"Cook A.D.; Hamilton J.A.; Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-&#x3B1; in rheumatoid arthritis: focus on mavrilimumab. Ther Adv Musculoskelet Dis 2018,10(2),29-38","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=16","first-page":"39","volume":"34","author":"Avci A.B.","year":"2016","unstructured":"Avci A.B.; Feist E.; Burmester G.R.; Targeting GM-CSF in rheumatoid arthritis. Clin Exp Rheumatol 2016,34(4)(Suppl. 98),39-44","journal-title":"Clin Exp Rheumatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1073\/pnas.91.12.5592","volume":"91","author":"Stanley E.","year":"1994","unstructured":"Stanley E.; Lieschke G.J.; Grail D.; Metcalf D.; Hodgson G.; Gall J.A.M.; Maher D.W.; Cebon J.; Sinickas V.; Dunn A.R.; Granulocyte\/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994,91(12),5592-5596","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3736\/jcim20090918","volume":"7","author":"Moher D.","year":"2009","unstructured":"Moher D.; Liberati A.; Tetzlaff J.; Altman D.G.; Altman D.; Antes G.; Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Chin Integr Med 2009,7(9),889-896","journal-title":"J Chin Integr Med"},{"key":"ref=19","unstructured":"Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 2011. Available from:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/handbook.cochrane.org\">http:\/\/handbook.cochrane.org"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/art.40420","volume":"70","author":"Burmester G.R.","year":"2018","unstructured":"Burmester G.R.; McInnes I.B.; Kremer J.M.; Miranda P.; Vencovsk&#xFD; J.; Godwood A.; Albulescu M.; Michaels M.A.; Guo X.; Close D.; Weinblatt M.; Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor &#x3B1; Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol 2018,70(5),679-689","journal-title":"Arthritis Rheumatol"},{"key":"ref=21","unstructured":"Study Quality Assessment Tools. National Heart, Lung, and Blood Institute (NHLBI). Available from:  https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/annrheumdis-2012-202450","volume":"72","author":"Burmester G.R.","year":"2013","unstructured":"Burmester G.R.; Weinblatt M.E.; McInnes I.B.; Porter D.; Barbarash O.; Vatutin M.; Szombati I.; Esfandiari E.; Sleeman M.A.; Kane C.D.; Cavet G.; Wang B.; Godwood A.; Magrini F.; Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis EARTH Study Group2013,72(9),1445-1452","journal-title":"Ann Rheum Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2016-210624","volume":"76","author":"Burmester G.R.","year":"2017","unstructured":"Burmester G.R.; McInnes I.B.; Kremer J.; Miranda P.; Korkosz M.; Vencovsky J.; Rubbert-Roth A.; Mysler E.; Sleeman M.A.; Godwood A.; Sinibaldi D.; Guo X.; White W.I.; Wang B.; Wu C.Y.; Ryan P.C.; Close D.; Weinblatt M.E.; A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis EARTH EXPLORER 1 study investigators2017,76(6),1020-1030","journal-title":"Ann Rheum Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/14397595.2014.896448","volume":"25","author":"Takeuchi T.","year":"2015","unstructured":"Takeuchi T.; Tanaka Y.; Close D.; Godwood A.; Wu C.Y.; Saurigny D.; Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study. Mod Rheumatol 2015,25(1),21-30","journal-title":"Mod Rheumatol"},{"key":"ref=25","first-page":"42","volume":"38","author":"Michael E.","year":"2017","unstructured":"Michael E.; Weinblatt, MD, 1 Iain B. McInnes, MD, 2 Joel M. Kremer, MD, 3 Pedro Miranda, MD, 4 Jiri Vencovsky, MD, 5 Xiang Guo, PhD, 6 Wendy I. White, PhD, 6 Patricia C. Ryan, PhD, 6 Alex Godwood, PhD, 7 Marius Albulescu, MD, 7 David Close, PhD, 7,^ and Ge M. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Int J Lab Hematol 2017,38(1),42-49","journal-title":"Int J Lab Hematol"},{"key":"ref=26","first-page":"73","volume":"37","author":"Mortensen J.H.","year":"2019","unstructured":"Mortensen J.H.; Guo X.; De Los Reyes M.; Dziegiel M.H.; Karsdal M.A.; Bay-Jensen A.C.; White W.I.; The VICM biomarker is released from activated macrophages and inhibited by anti-GM-CSFR&#x3B1;-mAb treatment in rheumatoid arthritis patients. Clin Exp Rheumatol 2019,37(1),73-80","journal-title":"Clin Exp Rheumatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1136\/ard.2010.146225","volume":"70","author":"Burmester G.R.","year":"2011","unstructured":"Burmester G.R.; Feist E.; Sleeman M.A.; Wang B.; White B.; Magrini F.; Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-&#x3B1;, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 2011,70(9),1542-1549","journal-title":"Ann Rheum Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1378\/chest.109.4.933","volume":"109","author":"Cottin V.","year":"1996","unstructured":"Cottin V.; T&#xE9;bib J.; Massonnet B.; Souquet P.J.; Bernard J.P.; Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996,109(4),933-8","journal-title":"Chest"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397116666201113085444","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187929\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397116666201113085444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:04:43Z","timestamp":1761332683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187929\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573397116666201113085444","relation":{},"ISSN":["1573-3971"],"issn-type":[{"type":"print","value":"1573-3971"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}